Daiichi Sankyo Advances CD37 ADC into Human Trials, Expanding Oncology Pipeline
Event summary
- Daiichi Sankyo has dosed the first patient in a Phase 1/2 trial of DS3790, a CD37-directed DXd antibody-drug conjugate (ADC).
- The trial will evaluate DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, enrolling approximately 420 patients globally.
- DS3790 represents Daiichi Sankyo's seventh DXd ADC in clinical development, leveraging its proprietary ADC technology.
- CD37 is a promising therapeutic target as it is overexpressed on malignant B-cells, and currently no CD37-directed therapies are approved.
The big picture
Daiichi Sankyo is doubling down on its ADC technology platform, aiming to address a significant unmet need in B-cell non-Hodgkin lymphoma, a market with over 600,000 new cases annually. The company's focus on DXd ADCs, leveraging its in-house technology, positions it as a key player in the rapidly evolving ADC landscape, but also exposes it to the inherent risks of early-stage clinical development. The trial's outcome will significantly influence investor perception of Daiichi Sankyo's oncology pipeline and its partnership strategy.
What we're watching
- Clinical Efficacy
- The trial's early data on safety and efficacy will be critical in determining DS3790's potential and Daiichi Sankyo's ADC strategy, particularly given the limited treatment options for relapsed/refractory B-cell lymphoma.
- Competitive Landscape
- The success of DS3790 will be weighed against other emerging therapies targeting B-cell malignancies, potentially impacting the commercial viability of Daiichi Sankyo's ADC portfolio.
- Partnership Dynamics
- The ongoing collaboration with AstraZeneca and Merck will be scrutinized to assess the overall success of Daiichi Sankyo’s ADC development and commercialization strategy, and whether further partnerships are likely.
Related topics